StockData
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3037% above fair value
$553.15−5.73 (-1.03%)

Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –

Vertex Pharmaceuticals Accrued royalties payable by Year

Accrued royalties payable ($M) ($M)

Vertex Pharmaceuticals Accrued royalties payable: $277M in FY2025, up 2.1% from a year earlier. That is the highest of the 11 years on record here.

Latest, FY2025
277
Period ended Dec 31, 2025
Change on a year earlier
+2.1%
271 in FY2024
History
11 years
Since FY2015
Sources
10
Documents cited below

Where the FY2025 figure comes from

Source: Form 10-K (filed 2026-02-13) ↗

Reported in Form 10-K Note (Accrued Expenses Breakdown).

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAccrued royalties payable ($M) ($M)Year on yearSource
FY2025Dec 31, 2025277+2.1%Form 10-K (filed 2026-02-13) ↗
FY2024Dec 31, 2024271+14.1%Form 10-K (filed 2026-02-13) ↗
FY2023Dec 31, 2023238+10.5%Form 10-K (filed 2025-02-13) ↗
FY2022Dec 31, 2022215+7.3%Form 10-K (filed 2024-02-15) ↗
FY2021Dec 31, 2021200+21.2%Form 10-K (filed 2023-02-10) ↗
FY2020Dec 31, 2020165+67.7%Form 10-K (filed 2022-02-09) ↗
FY2019Dec 31, 201998.6-2.5%Form 10-K (filed 2021-02-11) ↗
FY2018Dec 31, 2018101+38.5%Form 10-K (filed 2020-02-13) ↗
FY2017Dec 31, 201773+38.3%Form 10-K (filed 2019-02-13) ↗
FY2016Dec 31, 201652.8-12.3%Form 10-K (filed 2018-02-15) ↗
FY2015Dec 31, 201560.2–Form 10-K (filed 2017-02-23) ↗

Cite this data

StockData. (2026). Vertex Pharmaceuticals Accrued royalties payable ($M), annual FY2015–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/accrued-royalties

See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.